Recurrent Childhood Brain Tumor
9
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (9)
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Ex Vivo Drug Sensitivity Testing and Mutation Profiling
Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy
Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
Cilengitide in Treating Children With Refractory Primary Brain Tumors
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma